Amid derivatives of n-carbamide-substituted amino acids as modulators of formylpeptide receptor-1 (fprl-1)

FIELD: chemistry.

SUBSTANCE: invention relates to a compoundd represented by the formula

,

its enantiomers, diastereoisomers or pharmaceutically acceptable salts, which have modulatory activity against N-formylpeptide receptor-1 (FPRL-1). In formula II, a is 1, b is 0 or a is 1, b is 1; R1 is -OH; R2 is C1-8 Alkyl, optionally substituted by C6-10 aryl, amide or heterocycle, wherein the heterocycle is a 3 to 10-membered aromatic ring which contains at least one heteroatom selected from nitrogen, wherein one methylene group in the alkyl can be replaced by sulfur or sulphonyl; R3 is hydrogen or halogen; R4 is hydrogen; R5 is a halogen, -CF3 Or -S (O)nR14; N is 0, 1 or 2; R6 is hydrogen; R7 is hydrogen or halogen; R8 is hydrogen or C1-8 Alkyl; R9 is hydrogen, C1-8 Alkyl, Optionally substituted with a hydroxyl group, or C6-10 aryl; R10 is hydrogen, C1-8 alkyl optionally substituted with a hydroxyl group, or C6-10 aryl; R9a is hydrogen or C1-8 alkyl optionally substituted with a hydroxyl group; R10a is hydrogen or C1-8 alkyl optionally substituted with a hydroxyl group; R14 is CF3 or C1-8 alkyl.

EFFECT: increased activity of derivatives.

12 cl, 5 tbl, 4 ex

 



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention refers to peptide chemistry and concerns producing tripeptide diacetate H-β-Ala-Pro-DabNHBzl referred to a biologically active compound used in cosmetic industry as an active component for cosmetic products, particularly for stimulating skin rejuvenation, tightening and prevention. The method is based on the 6-staged synthesis and is free from the stages of setting and releasing the protective groups. The method involves proline β-chlorpionyl chloride acylation followed by producing N-(3-chlorpropionyl)proline pentafluorphenyl ester in the presence of N,N'-dicyclohexyl carbodiimide. The above pentafluorphenyl ester is condensed thereafter with glumatic acid monomethyl ester to produce N-(β-chlorpropionyl)-Pro-Glu(δ-OMe)OH. That is followed by benzylamine amidation in a combination with ammonolysis and chlorine substitution by an amino group. That enables producing the tripeptide β-Ala-Pro-Glu(δ-NH2)NHBzl; Hofmann rearrangement is conducted with the use of iodo-benzene diacetate to produce a target product.

EFFECT: method is characterised by simplicity, effectiveness; it is cost-effective and uses more accessible and cheap agents.

6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to prodrug preparations of glucagon superfamily peptides, in which the glucagon superfamily peptide is modified by binding a dipeptide with the peptide of the glucagon superfamily by an amide bond.

EFFECT: produgs, disclosed in the claimed invention, have an increased half-life and transfer into an active form in physiological conditions as a result of a non-enzymatic reaction, caused by chemical instability.

30 cl, 15 dwg, 8 tbl, 16 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutically acceptable crystalline or amorphous salts of D-isoglutamyl-D-tryptophan, methods of their obtaining, pharmaceutical compositions, containing them, and their application for obtaining pharmaceutical compositions for treatment of different conditions and/or diseases. In particular claimed invention relates to potassium salt of D-isoglutamyl-D-tryptophan (1:1) and magnesium salt of D-isoglutamyl-D-tryptophan (2:1).

EFFECT: obtaining pharmaceutically acceptable crystalline or amorphous salts of D-isoglutamyl-D-tryptophan.

22 cl, 15 dwg, 13 ex

FIELD: food industry.

SUBSTANCE: invention relates to fodder additives containing dipeptides or their salts; one amino acid residue of dipeptide is represented by DL-methionine residue; the other amino acid residue of dipeptide is represented by amino acid in L-configuration chosen from the group including lysine, threonine, tryptophan, histidine, valine, leucine, isoleucine, phenylalanine, arginine, cysteine and cystine.

EFFECT: described are fodder mixtures containing such additives and the said dipeptides production method.

31 cl, 17 dwg, 10 tbl, 25 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compounds, which can be used as inhibitors of protease of hepatitis C virus, pharmaceutical compositions, containing the said compounds, and methods of their application.

EFFECT: obtaining compounds which can be used as inhibitors of protease of hepatitis C virus.

41 cl, 10 dwg, 7 tbl, 26 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compounds, which can be used as inhibitors of protease of hepatitis C virus, to pharmaceutical compositions, which contain said compounds, and to methods of their application for treatment of diseases mediated by protease of hepatitis C virus.

EFFECT: obtaining compounds, which can be used as inhibitors of protease of hepatitis C virus.

37 cl, 22 dwg, 7 tbl, 34 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention described the macrocyclic compounds of formula wherein the radical values are presented in the patent claim. The above compounds are serine protease inhibitors wherein serine protease is hepatitis C virus (HCV) NS3 protease. This invention also discloses pharmaceutical compositions having antiviral activity against HCV, containing the claimed compounds, and one or more pharmaceutically acceptable carriers, as well as a method for preparing these compositions. The present invention describes a method of inhibiting the hepatitis C virus replication in a host, and a method of inhibiting activity of hepatitis C virus serine protease.

EFFECT: there are also presented a method of treating or preventing HCV infection, and a method of treating, preventing or ameliorating one or more symptoms of a liver disease or disorder associated with HCV infection in an individual.

69 cl, 39 ex, 8 tbl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I) a pharmaceutically acceptable salt thereof wherein each dash line (represented as ---) represents a double bond; X represents N or CH; R1a and R1b independently represent hydrogen or C1-6-jalkyl; L represents -O-; R2 represents hydrogen; R3 represents hydrogen or C1-6-alkyl; R4 represents quinolinyl substituted by one, two or three substitutes specified in C1-6-alkyl, C1-6-alkyloxy, thiazolyl or pyrazolyl, wherein said thiazolyl or pyrazolyl are substituted on any carbon atom by C1-6-alkyl; n is equal to 3, 4, 5 or 6; p is equal to 1 or 2. The invention refers to a pharmaceutical composition possessing the properties of KS3/4a-protease HCV inhibitors, containing a carrier, and an virally effective amount of the compound of formula (I) as an active ingredient. The method for preparing the compound of formula (I), wherein the above method involves forming an amide bond of an intermediate product (2a) and sulphonylamide (2b), as presented by the diagram, wherein G represents a group Also, the invention refers to alternative methods for preparing the compound of formula (I).

EFFECT: there are presented macrocyclic compounds possessing inhibitory activity on hepatitis C virus (HCV) replication.

13 cl, 1 tbl, 17 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: application describes prodrugs being 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-4-[4-(2-hydroxyethoxy)-phenyl]pyridine-3,5-dicarbonitryl derivatives, and a method for preparing them.

EFFECT: invention can find application in treating and/or preventing cardiovascular diseases.

8 cl, 4 tbl, 18 ex

FIELD: chemistry.

SUBSTANCE: disclosed is a method of producing pure crystalline D-isoglutamyl-D-trytophan which involves a step of removing protection from essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan or diester thereof to yield essentially pure D-isoglutamyl-D- tryptophan. An amorphous ammonium alt of D-isoglutamyl-D- tryptophan (1:1) is also disclosed. Also disclosed is a method of producing a pure monoammonium salt of D-isoglutamyl-D-tryptophan from essentially pure N-tert-butoxycarbonyl-D- isoglutamyl-D-tryptophan. Disclosed is a compound H-D-Glu-(γ-D-Trp-OR2)-α-OR1 and pharmaceutically acceptable acid addition salts thereof. Disclosed is a solid pharmaceutical composition and use thereof as an immunodepressant or anti-psoriasis agent.

EFFECT: improved method.

51 cl, 14 ex, 8 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound presented by formula OR or its pharmaceutically acceptable salt or solvate. The radical values are as follows: Rt - H, C1-C8 alkyl group, ammonium ion, alkali or alkali-earth ion; R84 - substituted C1-8 alkyl; R - C1-8 hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, (CH2)8(NHC(S)NH)Ph(SO2NH2), (CH2)dPh(SO2NH2), (CH2)5C(O)NH-(1-acetylpyrrolidin-2-yl)boric acid, (1-acetylpyrrolidin-2-yl)boric acid, (CH2)4CH(NH2)CO2H, (CH2)3CH(NH2)CO2H, (CH2)2CH(NH2)CO2H, -(CH2)d-R80, -C(O)(CH2)d-R80, or amino acid radical; R80 is carboxylate, C6-10 aryl, 3-6-merous heterocyclyl, amino acid; d represents an integer within 0 to 12 inclusively; and R82, R83, R85 and R86 are hydrogen, substituted or unsubstituted alkyl, ether, ester, CH2CH2OCH2CH3, CH2CH(OCH3)2, -(CH2)d-R80, or (CH2)dR87; wherein R87 represents phosphonate or phosphorinate. What is also presented is a complex containing the above compound and a radionuclide.

EFFECT: compound can be used as diagnostic or therapeutic agents.

11 cl, 13 dwg, 10 tbl, 23 ex

FIELD: chemistry.

SUBSTANCE: invention relates to heterocyclic compound of formula or to its pharmaceutically acceptable salt, where Alk represents linear C1-6 alkylene group, branched C1-6 alkylene group or C1-6 alkylene group, which has ring structure, where part of carbon atoms, constituting ring structure can be optionally substituted with oxygen atom, in ring X, X1 represents N or CRX1, X2 represents N or CRX2, X3 represents CRX3, X4 represents N or CRX4, where RX1, RX2, RX3 and RX4 each independently represents hydrogen atom; linear or branched C1-6alkyl group; linear or branched C1-6alcoxygroup; or halogen atom, in ring Y, Y1 represents CRY1, Y2 represents N or CRY2, Y3 represents N or CRY3, Y4 represents N or CRY4, RY1, RY2, RY3 and RY4 each independently represents hydrogen atom; linear or branched C1-6alkyl group, which can be substituted with halogen atom(s); C3-7alkyl group, which has ring structure; linear or branched C1-6alkoxygroup; halogen atom or cyanogroup, in ring Z, RZ represents linear or branched C1-6alkyl group, which can be substituted with halogen atom(s), or C3-7alkyl group, which has ring structure, which can be substituted with halogen atom(s). Invention also relates to particular compounds, DGAT1 inhibitor based on formula (I) compound, application of formula (I) compound, method of prevention or treatment of diseases, mediated by DGAT1 inhibition.

EFFECT: obtained are novel compounds, possessing useful biological activity.

19 cl, 19 tbl, 149 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing a compound of formula (I) which includes reacting a compound of formula (IV) with an oxalic acid diether of formula (V) . The invention also relates to intermediate compounds and methods for production thereof.

EFFECT: novel method of producing a compound having useful biological properties.

9 cl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to organic chemistry and specifically to compounds of formula or a pharmaceutically acceptable salt of such a compound, where - X is a carbon atom and R1a and R2a together form a bond; or - X is a carbon atom, R1a and R2a together form a bond, and R1 and R2 together form a moiety , where the asterisk shows the bonding site of R2; or - X is a carbon atom, R1a is hydrogen or (C1-4)alkoxy, and R2a is hydrogen; and R1 and R2, unless indicated otherwise, independently denote hydrogen; (C1-5)alkyl; aryl, where aryl denotes naphthyl or phenyl, where said aryl is unsubstituted or independently mono- or disubstituted, where the substitutes are independently selected from a group consisting of (C1-4)alkyl, (C1-4) alkoxy and halogen; or heteroaryl, selected from pyridyl, thienyl, oxazolyl or thiazolyl, where said heteroaryl is unsubstituted; under the condition that if R2 is aryl or heteroaryl, R1 cannot be aryl or heteroaryl, where the aryl and heteroaryl are independently unsubstituted or substituted as defined above; R3 is hydrogen or -CO-R31; R31 is (C1-5)alkyl, (C1-3)fluoroalkyl or (C3-6)cycloalkyl; n equals 1, 2, 3 or 4; B is a -(CH2)m- group, where m equals an integer from 1 to 3; A is-(CH2)P-, where p equals 2 or 3; R4 is (C1-5)alkyl; W is , where R5 is hydrogen or (C1-5)alkyl; R8, R9 and R10 is independently hydrogen, halogen, (C1-5)alkyl, hydroxy, -(C1-5)alkoxy, -O-CO-(C1-5)alkyl, (C1-3)fluoroalkyl, (C1-3)fluoroalkoxy, -CO-(C1-5)alkoxy, (C1-2)alkoxy-(C1-4)alkoxy or -NH-CO-(C1-5)alkyl. The invention also relates to a pharmaceutical composition based on a compound of formula (I).

EFFECT: novel compounds which are useful as calcium channel blockers are obtained.

11 cl, 2 tbl, 166 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to organic chemistry, namely to new phenylimidazole derivatives of general formula , wherein R1 represents a hydrogen atom, a phenyl lower-alkyl group or a pyridyl lower-alkyl group with a benzene ring and a pyridine ring are optionally substituted by 1 or 2 substitutes specified in a group consisting of halogen atoms, cyano group and halogen-substituted lower-alkyl groups; one or R2 and R3 represents a hydrogen atom, and another one represents a lower alkoxy group; R4 represents a lower-alkyl group, a difurylglyoxal group, a thienyl group or a phenyl group optionally substituted by 1 or 2 substitutes specified in a group consisting of lower-alkyl groups, lower-alkoxy groups, halogen atoms, a carboxyl group, lower alkoxycarbonyl groups, and halogen-substituted lower-alkyl groups; R5 and R6 are identical or different, and represent a hydrogen atom or a lower alkyl group; R7 and R8 are identical or different, and represent a hydrogen atom or a lower alkoxy group; provided R1 represents an unsubstituted phenyl lower-alkyl group, R2 represents a lower alkoxy group, R3 represents a hydrogen atom, R4 represents an unsubstituted phenyl group or a phenyl group containing 1 or 2 halogen-substituted lower-alkyl groups, and R5 represents a hydrogen atom, then R6 is other than a hydrogen atom. Also, the invention refers to an LPL activator, an agent for preventing or treating hyperlipidaemia, an agent for treating arteriosclerosis, and an agent for treating obesity on the basis of the compound of formula (1).

EFFECT: there are prepared new phenylimidazole derivatives effective for LPL activation.

23 cl, 10 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (I), where A is C-R1b; R1a, R1b, R1c, R1d, R1e, R2, R3, R4, R5 and n are as described in claim 1 of the invention, as well as pharmaceutically acceptable salts thereof. Described also is a pharmaceutical composition having activity as glucocorticoid receptor modulators.

EFFECT: novel compounds are obtained and described, which are glucocorticoid receptor antagonists and useful for treating and/or preventing diseases such as diabetes, dyslipidaemia, obesity, hyptension, cardiovascular diseases, adrenal gland malfunction or depression.

24 cl, 210 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of formula (I) and to their pharmaceutically acceptable salts wherein r represents 1; Ar is specified in and , R1 is specified in -COOR1a, -NHSO2R1b, -SO2NHR1d, -SO2OH, -O-CH(R1e)-COOH and tetrazol-5-yl, R1a represents H, -C1-6alkyl, -C1-3alkylenaryl, -C1-3alkyleneheteroaryl, - C3-7cycloalkyl, -CH(C1-4alkyl)OC(O)R1aa, or R1aa represents -O-C1-6alkyl or -O-C3-7cycloalkyl; R1b represents R1c; R1d represents -C1-6alkyl or -C0-4alkylenaryl; R1d represents -C(O)R1c or -C(O)NHR1c; R1e represents -C1-4alkyl; Y represents -C(R3)-, Z represents -N-, Q represents -C(R2)-, and W represents a bond; Y represents -N-, Z represents -C(R3)-, Q represents -C(R2)-, and W represents a bond; Y represents -C(R3)-, Z represents -N-, Q represents -N-, and W represents a bond; or Y represents -C(R3)-, Z represents -CH-, Q represents -C(R2)-, and W represents -C(O)-; R2 is specified in H, halogen, -C1-6alkyl, -C3-6dicloalkyl, and -C0-5alkylene-OR2b; wherein R2b is specified in H and -C1-6alkyl; R3 is specified in -C1-10alkyl and -C0-5alkylene-O-C0-5alkylene-R3b; and R3b represents -C1-6alkyl; X represents -C1-12alkylene-, where at least one group -CH2- in alkylene is substituted by the group -NR4a-C(O)- or -C(O)-NR4a-, wherein R4a is specified in H, -OH, and -C1-4aalkyl; R5 is specified in -C0-3 alkylene-SR5a, -C0-3alkylene-C(O)NR5bR5c, -C0-3alkylene-NR5b-C(O)R5d, -NH-C0-1alkylene-P(O)(OR5e)2, -C0-2alkylene-CHR5g-COOH and -C0-3alkylene-C(O)NR5h-CHR5i-COOH; R5a represents H or -C(O)-R5aa; R5aa represents -C1-6alkyl, -C0-6alkylene-C3-7cycoalkyl, -C0-6alkylenaryl, or -C0-6alkylenemorpholine; R5b represents -OH, -OC(O)R5ba, -CH2COOH or -OC(S)NR5bbR5bc; R5ba represents -C1-6alkyl, -OCH2-aryl or -CH2O-aryl; R5bb and R5bc independently represents -C1-4alkyl; R5c represents H; R5d represents H; R5e represents H; R5g represents H or -CH2-O-(CH2)2-O-CH3; R5h represents H; R5i represents -C0-3alkylenaryl; R6 is specified in -C1-6alkyl, -C0-3alkylenaryl, -C0-3alkyleneheteroaryl and -C0-3alkylene-C3-7cycloalkyl; and R7 represents H or together with R6 to form -C3-7cycloalkyl; where each ring in Ar and each aryl and heteroaryl in R1-3 and R5-6 are optionally substituted by 1-3 substitutes optionally specified in -C1-6alkyl, -CN, halogen, -O-C1-6alkyl, -phenyl, -NO2, wherein each alkyl is optionally substituted by 1-5 fluorine atoms; each carbon atom in X is optionally substituted by one or more groups R4b, and one group -CH2- in X may be substituted by -C4-8cycloalkylene- and -CH=CR4d-; where R4b is specified in -C0-5alkylene-COOR4c and benzene, where R4c represents H; and R4d represents -CH2-thiophen; each alkyl and each aryl in R1-3, R4a-4d and R5-6 are optionally substituted by 1-7 fluorine atoms; where aryl represents monovalent aromatic hydrocarbon having one ring or condensed rings, and contains 6-10 carbon atoms in the ring; and heteroaryl represents a monovalent aromatic group having one ring or two condensed rings, and having 5-10 atoms in large in the ring with one atom of the ring represents a heteroatom specified in nitrogen, oxygen and sulphur. Besides, the invention refers to a pharmaceutical composition based on the compound of formula

,

to a method for preparing the compound of formula (I), to intermediate compounds used in synthesis of the compound of formula (I), to the use of the compounds of formula (I).

EFFECT: there are prepared new compounds possessing activity of a type 1 angiotensin II (AT1) receptor antagonist and activity of neprilysin inhibition.

38 cl, 36 ex

FIELD: medicine.

SUBSTANCE: invention refers to using a compound of formula wherein R represents hydrogen, lower alkyl or amino; X-R1 represents -CH2- or -CH(lower alkoxy)- and Y-R2 represents -CH2-, -CH(lower alkyl)-, -O-, -S-, -S(O)- or -S(O)2-; Ar represents phenyl, naphthyl or benzofuranyl rings of which are substituted by one or more substitutes specified in a group consisting of lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, lower alkoxy substituted by halogen, hydroxy, dialkylamino, morpholine, benzyl or O-benzyl; or pharmaceutically acceptable acid addition salts for preparing a drug for treating depression, anxiety disorders, bipolar disorder, schizophrenia, Parkinson's disease, epilepsy, migraine, diabetes, diabetic complications or disorders and disturbances of body temperature homeostasis. Also, the invention refers to specific compounds, to the drug on the basis of declared compounds.

EFFECT: there are studied known imidazole derivative, and also there are produced new imidazole derivative showing high affinity to trace amine receptors.

6 cl, 48 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to organic chemistry, particularly to a method of producing trans-urocanic acid, which involves treating D-glucose with aqueous ammonia and formalin in molar ratio D-glucose: aqueous ammonia: formalin equal to 1:24:2.7, in water in the presence of basic copper carbonate at temperature 85-90°C for 3 hours to form (1S,2S,3S)-1-(1H-imidazol-4-yl)-butane-1,2,3,4-tetrazole, which is extracted in form of a hydrochloride. Through periodate splitting in water, the obtained (1S,2S,3S)-1-(1H-imidazol-4-yl)-butane-1,2,3,4-tetrazole is converted at room temperature to 1H-imidazole-4-carbaldehyde, condensation of which, in acetic anhydride in the presence of anhydrous potassium acetate at temperature 120°C for 2 hours, leads to formation of trans-urocanic acid with subsequent extraction thereof from the reaction mass.

EFFECT: novel method of producing trans-urocanic acid which is based on use of cheap and readily available initial reagents.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a compound of formula I ; or to its pharmaceutically acceptable salts where n represents 0, 1 or 2; Y1 represents a bond or a group C(O); Y2, represents a bond, the groups C(O) or S(O)2; R1 represents hydrogen, halogen, cyano, C1-2alkyl; R2 represents hydrogen, halogen, cyano, C1-4alkyl, C1-3alkoxy, halogen-substituted-C1-3alkyl, halogen-substituted-C1-3alkoxyl, C6aryl-C0alkyl, tetrazolyl, C3-6cycloalkyl-C0alkyl, C6-7heterocycloalkyl-C0-4alkyl where 1 or 2 carbon atoms in the ring are substituted by the groups selected from -O-, -NH-, -S(O) and -SO2-; and phenoxy groups; where said aryl and heterocycloalkyl groups R2 can be substituted by 1 or 2 radicals independently selected from C1-6alkyl; R3 represents hydrogen, halogen, cyano, C1-3alkoxy or halogen-substituted-C1-2alkyl group and a group -NR6aR6b where R6a and R6b are independently selected from hydrogen and C1-4alkyl; R4 represents hydrogen, halogen, cyano, C1-3alkoxy or halogen-substituted-C1-2alkyl group; R5 represents hydrogen or C1-3alkyl group; L represents a bivalent radical selected from ; ; ; ; ; ; ; ; ; ; ; ; and ; where asterisks the junctions of Y2 and R2; where any bivalent radical L can be substituted by 1 or 2 radicals independently selected from halogen, hydroxy, cyano, C1-4alkyl, C1-4alkyl carbonylamino, C1-4alkoxy, C1-4alkoxycarbonyl, halogen-substituted - C1-4alkyl, C1-3alkylsulfonyl, C1-3alkylsulfonyl-amino, cyano-substituted - C1-4alkyl and halogen-substituted -C1-4alkoxy radicals. Also, the invention refers to a method of Hedgehog path inhibition in a cell and to a method of undesired cell proliferation inhibition which involves the interaction of the compound of formula I and the cell.

EFFECT: new substituted imidazole derivatives which can be effective in treatment of some types of cancer are prepared.

13 cl, 1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of general formula (1), in which Y1, Y1', Y2, Y2', Y3, Y3', Y4 and Y4' denote -H; R1 and R2 denote an unsubstituted -C1-8-aliphatic; R3 denotes an unsubstituted -C6-16-aryl; R4 denotes -H or -C(=O)R0, where R0 denotes -C1-8-aliphatic, unsubstituted or mono- or polysubstituted with substitutes independently selected from a group consisting of -F, -Cl, -Br, -I and -CN; Q denotes unsubstituted -C1-8-aliphatic-heteroaryl; X denotes =O, =CR6R7 or =N-R6, wherein R5 denotes -NH2, -NH-(unsubstituted-C1-8-aliphatic) or -N-(unsubstituted-C1-8-aliphatic)2, if X denotes =O, or R5 and R6 together form a 5-member ring in which the remaining ring atoms independently denote C, N, S or O, wherein the 5-member ring denotes 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, oxazolyl or thiazolyl, in each case unsubstituted or monosubstituted with unsubstituted C1-C8aliphatic or =O, or unsubstituted tetrazolyl, if X denotes =N-R6, or R5 and R6 together form unsubstituted phenyl, and R7 denotes -H, if X denotes =CR6R7, where "aliphatic" in each case represents a branched or straight, saturated hydrocarbon residue; "aryl" in each case independently denotes a carboxylic ring system containing at least one aromatic ring which does not contain heteroatoms, where the aryl may be optionally condensed with other saturated, (partially) unsaturated or aromatic ring systems; "heteroaryl" denotes indolyl; in the form of a separate stereoisomer or a mixture thereof, in the form of free compounds and/or physiologically compatible salts thereof. The compound of formula

is used to obtain a medicinal agent having affinity for the µ-opioid receptor and the ORL1-receptor, and for treating pain.

EFFECT: substituted cyclohexyldiamines, having affinity for the µ-opioid receptor and the ORL1-receptor.

7 cl, 1 tbl, 29 ex

Up!